



SPARC/Sec/SE/2022-23/98

January 25, 2023

To,

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/Madam,

Sub: Announcement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

We would like to inform that the Company has received an intimation from the partner about the launch of SEZABY™ (phenobarbital sodium powder for injection) in the U.S. for the treatment of neonatal seizures. The Company is eligible to receive US\$ 5 million as milestone payment upon commercialization of SEZABY, the first and only product approved in U.S. for the treatment of neonatal seizures in term and preterm infants.

Pursuant to the agreement between the parties, SPARC shall also be eligible for future milestones and royalties on net sales.

This is for your information and dissemination purpose.

Yours faithfully,

For Sun Pharma Advanced Research Company Ltd.

Chetan Rajpara
Chief Financial Officer